Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A SR in Mild to Moderate Alzheimer's
NCT01282619Phase 3Unknown
- Sponsor
- Luye Pharma Group
- Start
- May 2010
- Primary completion
- Jun 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Huperzine A in Alzheimer's disease (AD), sponsored by Luye Pharma Group. Status: unknown.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01282619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282619.